Search

Your search keyword '"Rosenthal, David I."' showing total 1,296 results
Start Over Author "Rosenthal, David I."
1,296 results on '"Rosenthal, David I."'

1. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

Author

Gillison, Maura L, Ferris, Robert L, Harris, Jonathan, Colevas, A Dimitrios, Mell, Loren K, Kong, Christina, Jordan, Richard C, Moore, Kevin L, Truong, Minh-Tam, Kirsch, Claudia, Chakravarti, Arnab, Blakaj, Dukagjin M, Clump, David A, Ohr, James P, Deeken, John F, Gensheimer, Michael F, Saba, Nabil F, Dorth, Jennifer A, Rosenthal, David I, Leidner, Rom S, Kimple, Randall J, Machtay, Mitchell, Curran, Walter J, Torres-Saavedra, Pedro, and Le, Quynh Thu

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Immunotherapy, Radiation Oncology, Dental/Oral and Craniofacial Disease, Cancer, Orphan Drug, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Humans, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Cisplatin, Carcinoma, Squamous Cell, Mucositis, Neoplasm Recurrence, Local, Head and Neck Neoplasms, Fatigue, Other Physical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeProgrammed death-1 immune checkpoint blockade improves survival of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but the benefits of addition to (chemo)radiation for newly diagnosed patients with HNSCC remain unknown.Methods and materialsWe evaluated the safety of nivolumab concomitant with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1), every 3-week cisplatin (arm 2), cetuximab (arm 3), or alone for platinum-ineligible patients (arm 4) in newly diagnosed intermediate- or high-risk locoregionally advanced HNSCC. Patients received nivolumab from 2 weeks prior to radiation therapy until 3 months post-radiation therapy. The primary endpoint was dose-limiting toxicity (DLT). If ≤2 of the first 8 evaluable patients experienced a DLT, an arm was considered safe. Secondary endpoints included toxicity and feasibility of adjuvant nivolumab to 1 year, defined as all 7 additional doses received by ≥4 of the first 8 evaluable patients across arms.ResultsOf 39 patients (10 in arms 1, 3, 4 and 9 in arm 2), 72% had T3-4 tumors, 85% had N2-3 nodal disease, and 67% had >10 pack-years of smoking. There were no DLTs in arms 1 and 2, 1 in arm 3 (mucositis), and 2 in arm 4 (lipase elevation and mucositis in 1 and fatigue in another). The most common grade ≥3 nivolumab-related adverse events were lipase increase, mucositis, diarrhea, lymphopenia, hyponatremia, leukopenia, fatigue, and serum amylase increase. Adjuvant nivolumab was feasible as defined in the protocol.ConclusionsConcomitant nivolumab with the 4 tested regimens was safe for patients with intermediate- and high-risk HNSCC, and subsequent adjuvant nivolumab was feasible as defined (NCT02764593).

Published
2023

2. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234

Author

Michikawa, Chieko, Torres-Saavedra, Pedro A, Silver, Natalie L, Harari, Paul M, Kies, Merrill S, Rosenthal, David I, Le, Quynh-Thu, Jordan, Richard C, Duose, Dzifa Y, Mallampati, Saradhi, Trivedi, Sanchit, Luthra, Rajyalakshmi, Wistuba, Ignacio I, Osman, Abdullah A, Lichtarge, Olivier, Foote, Robert L, Parvathaneni, Upendra, Hayes, D Neil, Pickering, Curtis R, and Myers, Jeffrey N

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Dental/Oral and Craniofacial Disease, Radiation Oncology, Rare Diseases, Clinical Trials and Supportive Activities, Orphan Drug, Digestive Diseases, 4.2 Evaluation of markers and technologies, 6.1 Pharmaceuticals, Detection, screening and diagnosis, Evaluation of treatments and therapeutic interventions, AMP Exception, Oncology and carcinogenesis
Abstract

PurposeAn evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing TP53 missense mutations as high-risk, associated with poor outcomes, or low-risk, with similar outcomes as TP53 wild-type, and has been validated as a reliable prognostic marker. We performed this study to further validate prior findings demonstrating that EAp53 is a prognostic marker for patients with locally advanced HNSCC and explored its predictive value for treatment outcomes to adjuvant bio-chemoradiotherapy.Methods and materialsEighty-one resection samples from patients treated surgically for stage III or IV human papillomavirus-negative HNSCC with high-risk pathologic features, who received either radiation therapy + cetuximab + cisplatin (cisplatin) or radiation therapy + cetuximab + docetaxel (docetaxel) as adjuvant treatment in a phase 2 study were subjected to TP53 targeted sequencing and EAp53 scoring to correlate with clinical outcomes. Due to the limited sample size, patients were combined into 2 EAp53 groups: (1) wild-type or low-risk; and (2) high-risk or other.ResultsAt a median follow-up of 9.8 years, there was a significant interaction between EAp53 group and treatment for overall survival (P = .008), disease-free survival (P = .05), and distant metastasis (DM; P = .004). In wild-type or low-risk group, the docetaxel arm showed significantly better overall survival (hazard ratio [HR] 0.11, [0.03-0.36]), disease-free survival (HR 0.24, [0.09-0.61]), and less DM (HR 0.04, [0.01-0.31]) than the cisplatin arm. In high-risk or other group, differences between treatments were not statistically significant.ConclusionsThe docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.

Published
2022

5. Impact of Cancer Care Regionalization on Patient Volume

Author

Contrera, Kevin J., Tam, Samantha, Pytynia, Kristen, Diaz Jr., Eduardo M., Hessel, Amy C., Goepfert, Ryan P., Lango, Miriam, Su, Shirley Y., Myers, Jeffrey N., Weber, Randal S., Eguia, Arturo, Pisters, Peter W. T., Adair, Deborah K., Nair, Ajith S., Rosenthal, David I., Mayo, Lauren, Chronowski, Gregory M., Zafereo, Mark E., and Shah, Shalin J.

Published
2023
Full Text
View/download PDF

6. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis

Author

Gharzai, Laila A, Morris, Emily, Suresh, Krithika, Nguyen-Tân, Phuc Felix, Rosenthal, David I, Gillison, Maura L, Harari, Paul M, Garden, Adam S, Koyfman, Shlomo, Caudell, Jimmy J, Jones, Christopher U, Mitchell, Darrion L, Krempl, Greg, Ridge, John A, Gensheimer, Michael F, Bonner, James A, Filion, Edith, Dunlap, Neal E, Stokes, William A, Le, Quynh-Thu, Torres-Saavedra, Pedro, Mierzwa, Michelle, and Schipper, Matthew J

Published
2024
Full Text
View/download PDF

7. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy

Author

Maroongroge, Sean, Mohamed, Abdallah SR., Nguyen, Callistus, Guma De la Vega, Jean, Frank, Steven J., Garden, Adam S., Gunn, Brandon G., Lee, Anna, Mayo, Lauren, Moreno, Amy, Morrison, William H., Phan, Jack, Spiotto, Michael T., Court, Laurence E., Fuller, Clifton D., Rosenthal, David I., and Netherton, Tucker J.

Published
2024
Full Text
View/download PDF

9. The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/− systemic therapy in locally advanced head and neck cancer

Author

Kish, Julie A, Zhang, Qiang, Langer, Corey J, Nguyen-Tân, Phuc Felix, Rosenthal, David I, Weber, Randal S, List, Marcy A, Wong, Stuart J, Garden, Adam S, Hu, Kenneth, Trotti, Andy M, Bonner, James A, Jones, Christopher U, Yom, Sue S, Thorstad, Wade, Schultz, Christopher J, Ridge, John A, Shenouda, George, Harris, Jonathan, and Le, Quynh-Thu

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Dental/Oral and Craniofacial Disease, Cancer, Rare Diseases, Clinical Research, Aged, Chemoradiotherapy, Head and Neck Neoplasms, Humans, Prognosis, Proportional Hazards Models, Retrospective Studies, Locally advanced head and neck cancer, Chemotherapy, Radiation, Older Adult, Age, Toxicity, CSS, OS, Retrospective analysis, Oncology and carcinogenesis
Abstract

PurposeTo examine the role age plays in the treatment and prognosis of locally advanced head and neck cancer (LAHNC) treated definitively with radiation alone or combined modality therapy.MethodsA retrospective analysis was performed of three NRG/RTOG trials examining either radiation alone or combined radiation and systemic therapy for LAHNC. The effect of age (≥70 yrs.) on cause-specific survival (CSS), overall survival (OS), and toxicity was evaluated.ResultsA total of 2688 patients were analyzed, of whom 309 patients (11.5%) were ≥ 70. For all studies combined, the hazard ratio (HR) for CSS for patients age ≥ 70 vs. those

Published
2021

10. Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention.

Author

Peterson, Susan K, Basen-Engquist, Karen, Demark-Wahnefried, Wendy, Prokhorov, Alexander V, Shinn, Eileen H, Martch, Stephanie L, Beadle, Beth M, Garden, Adam S, Farcas, Emilia, Brandon Gunn, G, Fuller, Clifton D, Morrison, William H, Rosenthal, David I, Phan, Jack, Eng, Cathy, Cinciripini, Paul M, Karam-Hage, Maher A, Camero Garcia, Maria, and Patrick, Kevin

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Prevention, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, Dental/Oral and Craniofacial Disease, Cancer, Colo-Rectal Cancer, Digestive Diseases, Good Health and Well Being, Cancer Survivors, Deglutition Disorders, Feasibility Studies, Head and Neck Neoplasms, Humans, Technology
Abstract

Objectives. Remote monitoring (RM) of health-related outcomes may optimize cancer care and prevention outside of clinic settings. CYCORE is a software-based system for collection and analyses of sensor and mobile data. We evaluated CYCORE's feasibility in studies assessing: (1) physical functioning in colorectal cancer (CRC) patients; (2) swallowing exercise adherence in head and neck cancer (HNC) patients during radiation therapy; and (3) tobacco use in cancer survivors post-tobacco treatment (TTP). Methods. Participants completed RM: for CRC, blood pressure, activity, GPS; for HNC, video of swallowing exercises; for TTP, expired carbon monoxide. Patient-reported outcomes were assessed daily. Results. For CRC, HNC and TTP, respectively, 50, 37, and 50 participants achieved 96%, 84%, 96% completion rates. Also, 91-100% rated ease and self-efficacy as highly favorable, 72-100% gave equivalent ratings for overall satisfaction, 72-93% had low/no data privacy concerns. Conclusion. RM was highly feasible and acceptable for patients across diverse use cases.

Published
2021

11. Longitudinal diffusion and volumetric kinetics of head and neck cancer magnetic resonance on a 1.5 T MR-linear accelerator hybrid system: A prospective R-IDEAL stage 2a imaging biomarker characterization/pre-qualification study

Author

El-Habashy, Dina M., Wahid, Kareem A., He, Renjie, McDonald, Brigid, Rigert, Jillian, Mulder, Samuel J., Lim, Tze Yee, Wang, Xin, Yang, Jinzhong, Ding, Yao, Naser, Mohamed A., Ng, Sweet Ping, Bahig, Houda, Salzillo, Travis C., Preston, Kathryn E., Abobakr, Moamen, Shehata, Mohamed A., Elkhouly, Enas A., Alagizy, Hagar A., Hegazy, Amira H., Mohammadseid, Mustefa, Terhaard, Chris, Philippens, Marielle, Rosenthal, David I., Wang, Jihong, Lai, Stephen Y., Dresner, Alex, Christodouleas, John C., Mohamed, Abdallah Sherif Radwan, and Fuller, Clifton D.

Published
2023
Full Text
View/download PDF

12. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer

Author

Caudell, Jimmy J., Torres-Saavedra, Pedro A., Rosenthal, David I., Axelrod, Rita S., Nguyen-Tan, Phuc Felix, Sherman, Eric J., Weber, Randal S., Galvin, James M., El-Naggar, Adel K., Konski, Andre A., Echevarria, Michelle I., Dunlap, Neal E., Shenouda, George, Singh, Anurag K., Beitler, Jonathan J., Garsa, Adam, Bonner, James A., Garden, Adam S., Algan, Ozer, Harris, Jonathan, and Le, Quynh-Thu

Published
2023
Full Text
View/download PDF

13. Head and neck surgical oncology in the time of a pandemic: Subsite‐specific triage guidelines during the COVID‐19 pandemic

Author

Consortium, Anderson Head and Neck Surgery Treatment Guidelines, members:, Consortium, Maniakas, Anastasios, Jozaghi, Yelda, Zafereo, Mark E, Sturgis, Erich M, Su, Shirley Y, Gillenwater, Ann M, Gidley, Paul W, Lewis, Carol M, Diaz, Eduardo, Goepfert, Ryan P, Kupferman, Michael E, Gross, Neil D, Hessel, Amy C, Pytynia, Kristen B, Nader, Marc‐Elie, Wang, Jennifer R, Lango, Miriam N, Kiong, Kimberley L, Guo, Theresa, Zhao, Xiao, Yao, Christopher MKL, Appelbaum, Eric, Alpard, Jennifer, Garcia, Jose A, Terry, Shawn, Flynn, Jill E, Bauer, Sarah, Fournier, Danielle, Burgess, Courtlyn G, Wideman, Cayla, Johnston, Matthew, You, Chenxi, De Luna, Rolando, Joseph, Liza, Diersing, Julia, Prescott, Kaitlin, Heiberger, Katherine, Mugartegui, Lilian, Rodriguez, Jessica, Zendehdel, Sara, Sellers, Justin, Friddell, Rebekah A, Thomas, Ajay, Khanjae, Sonam J, Schwarzlose, Katherine B, Chambers, Mark S, Hofstede, Theresa M, Cardoso, Richard C, Wesson, Ruth Aponte, Won, Alex, Otun, Adegbenga O, Gombos, Dan S, Al‐Zubidi, Nagham, Hutcheson, Katherine A, Gunn, G Brandon, Rosenthal, David I, Gillison, Maura L, Ferrarotto, Renata, Weber, Randal S, Hanna, Ehab Y, Myers, Jeffrey N, and Lai, Stephen Y

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Dental/Oral and Craniofacial Disease, Clinical Research, Rare Diseases, Prevention, Cancer, Good Health and Well Being, Betacoronavirus, COVID-19, Cancer Care Facilities, Communicable Disease Control, Consensus, Coronavirus Infections, Female, Head and Neck Neoplasms, Humans, Male, Occupational Health, Outcome Assessment, Health Care, Pandemics, Patient Selection, Pneumonia, Viral, Practice Guidelines as Topic, SARS-CoV-2, Surgical Oncology, Triage, United States, oncology, otolaryngology, MD Anderson Head and Neck Surgery Treatment Guidelines Consortium, Consortium members, Dentistry, Otorhinolaryngology, Clinical sciences
Abstract

BackgroundCOVID-19 pandemic has strained human and material resources around the world. Practices in surgical oncology had to change in response to these resource limitations, triaging based on acuity, expected oncologic outcomes, availability of supportive resources, and safety of health care personnel.MethodsThe MD Anderson Head and Neck Surgery Treatment Guidelines Consortium devised the following to provide guidance on triaging head and neck cancer (HNC) surgeries based on multidisciplinary consensus. HNC subsites considered included aerodigestive tract mucosa, sinonasal, salivary, endocrine, cutaneous, and ocular.RecommendationsEach subsite is presented separately with disease-specific recommendations. Options for alternative treatment modalities are provided if surgical treatment needs to be deferred.ConclusionThese guidelines are intended to help clinicians caring for patients with HNC appropriately allocate resources during a health care crisis, such as the COVID-19 pandemic. We continue to advocate for individual consideration of cases in a multidisciplinary fashion based on individual patient circumstances and resource availability.

Published
2020

14. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic.

Author

MD Anderson Head and Neck Surgery Treatment Guidelines Consortium, Consortium members, Maniakas, Anastasios, Jozaghi, Yelda, Zafereo, Mark E, Sturgis, Erich M, Su, Shirley Y, Gillenwater, Ann M, Gidley, Paul W, Lewis, Carol M, Diaz, Eduardo, Goepfert, Ryan P, Kupferman, Michael E, Gross, Neil D, Hessel, Amy C, Pytynia, Kristen B, Nader, Marc-Elie, Wang, Jennifer R, Lango, Miriam N, Kiong, Kimberley L, Guo, Theresa, Zhao, Xiao, Yao, Christopher MKL, Appelbaum, Eric, Alpard, Jennifer, Garcia, Jose A, Terry, Shawn, Flynn, Jill E, Bauer, Sarah, Fournier, Danielle, Burgess, Courtlyn G, Wideman, Cayla, Johnston, Matthew, You, Chenxi, De Luna, Rolando, Joseph, Liza, Diersing, Julia, Prescott, Kaitlin, Heiberger, Katherine, Mugartegui, Lilian, Rodriguez, Jessica, Zendehdel, Sara, Sellers, Justin, Friddell, Rebekah A, Thomas, Ajay, Khanjae, Sonam J, Schwarzlose, Katherine B, Chambers, Mark S, Hofstede, Theresa M, Cardoso, Richard C, Wesson, Ruth Aponte, Won, Alex, Otun, Adegbenga O, Gombos, Dan S, Al-Zubidi, Nagham, Hutcheson, Katherine A, Gunn, G Brandon, Rosenthal, David I, Gillison, Maura L, Ferrarotto, Renata, Weber, Randal S, Hanna, Ehab Y, Myers, Jeffrey N, and Lai, Stephen Y

Subjects
MD Anderson Head and Neck Surgery Treatment Guidelines Consortium, Consortium members, Humans, Pneumonia, Viral, Coronavirus Infections, Head and Neck Neoplasms, Consensus, Communicable Disease Control, Patient Selection, Occupational Health, Cancer Care Facilities, Triage, United States, Female, Male, Practice Guidelines as Topic, Pandemics, Patient Safety, Surgical Oncology, Betacoronavirus, Outcome Assessment, Health Care, COVID-19, SARS-CoV-2, oncology, otolaryngology, Outcome Assessment, Health Care, Pneumonia, Viral, Otorhinolaryngology, Clinical Sciences, Dentistry
Abstract

BackgroundCOVID-19 pandemic has strained human and material resources around the world. Practices in surgical oncology had to change in response to these resource limitations, triaging based on acuity, expected oncologic outcomes, availability of supportive resources, and safety of health care personnel.MethodsThe MD Anderson Head and Neck Surgery Treatment Guidelines Consortium devised the following to provide guidance on triaging head and neck cancer (HNC) surgeries based on multidisciplinary consensus. HNC subsites considered included aerodigestive tract mucosa, sinonasal, salivary, endocrine, cutaneous, and ocular.RecommendationsEach subsite is presented separately with disease-specific recommendations. Options for alternative treatment modalities are provided if surgical treatment needs to be deferred.ConclusionThese guidelines are intended to help clinicians caring for patients with HNC appropriately allocate resources during a health care crisis, such as the COVID-19 pandemic. We continue to advocate for individual consideration of cases in a multidisciplinary fashion based on individual patient circumstances and resource availability.

Published
2020

15. Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer

Author

Mell, Loren K, Shen, Hanjie, Nguyen-Tân, Phuc Felix, Rosenthal, David I, Zakeri, Kaveh, Vitzthum, Lucas K, Frank, Steven J, Schiff, Peter B, Trotti, Andy M, Bonner, James A, Jones, Christopher U, Yom, Sue S, Thorstad, Wade L, Wong, Stuart J, Shenouda, George, Ridge, John A, Zhang, Qiang E, and Le, Quynh-Thu

Subjects
Cancer, Rare Diseases, Clinical Research, Dental/Oral and Craniofacial Disease, Adult, Aged, Aged, 80 and over, Case-Control Studies, Chemoradiotherapy, Female, Follow-Up Studies, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Nomograms, Prognosis, Survival Rate, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePrevious studies indicate that the benefit of therapy depends on patients' risk for cancer recurrence relative to noncancer mortality (ω ratio). We sought to test the hypothesis that patients with head and neck cancer (HNC) with a higher ω ratio selectively benefit from intensive therapy.Experimental designWe analyzed 2,688 patients with stage III-IVB HNC undergoing primary radiotherapy (RT) with or without systemic therapy on three phase III trials (RTOG 9003, RTOG 0129, and RTOG 0522). We used generalized competing event regression to stratify patients according to ω ratio and compared the effectiveness of intensive therapy as a function of predicted ω ratio (i.e., ω score). Intensive therapy was defined as treatment on an experimental arm with altered fractionation and/or multiagent concurrent systemic therapy. A nomogram was developed to predict patients' ω score on the basis of tumor, demographic, and health factors. Analysis was by intention to treat.ResultsDecreasing age, improved performance status, higher body mass index, node-positive status, P16-negative status, and oral cavity primary predicted a higher ω ratio. Patients with ω score ≥0.80 were more likely to benefit from intensive treatment [5-year overall survival (OS), 70.0% vs. 56.6%; HR of 0.73, 95% confidence interval (CI): 0.57-0.94; P = 0.016] than those with ω score

Published
2019

16. Temporal characterization of acute pain and toxicity kinetics during radiation therapy for head and neck cancer. A retrospective study

Author

Salama, Vivian, Youssef, Sara, Xu, Tianlin, Wahid, Kareem A., Chen, Jaime, Rigert, Jillian, Lee, Anna, Hutcheson, Katherine A., Gunn, Brandon, Phan, Jack, Garden, Adam S., Frank, Steven J., Morrison, William, Reddy, Jay P., Spiotto, Michael T., Naser, Mohammed A., Dede, Cem, He, Renjie, Mohammed, Abdallah S.R., van Dijk, Lisanne V., Lin, Ruitao, Roldan, Carlos J., Rosenthal, David I., Fuller, Clifton D., and Moreno, Amy C.

Published
2023
Full Text
View/download PDF

17. ASO Visual Abstract: Impact of Cancer Care Regionalization on Patient Volume

Author

Contrera, Kevin J., Tam, Samantha, Pytynia, Kristen, Diaz, Jr., Eduardo M., Hessel, Amy C., Goepfert, Ryan P., Lango, Miriam, Su, Shirley Y., Myers, Jeffrey N., Weber, Randal S., Eguia, Arturo, Pisters, Peter W. T., Adair, Deborah K., Nair, Ajith S., Rosenthal, David I., Mayo, Lauren, Chronowski, Gregory M., Zafereo, Mark E., and Shah, Shalin J.

Published
2023
Full Text
View/download PDF

18. Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials

Author

Fakhry, Carole, Zhang, Qiang, Gillison, Maura L, Nguyen‐Tân, Phuc Felix, Rosenthal, David I, Weber, Randal S, Lambert, Louise, Trotti, Andy M, Barrett, William L, Thorstad, Wade L, Yom, Sue S, Wong, Stuart J, Ridge, John A, Rao, Shyam SD, Spencer, Sharon, Fortin, Andre, Raben, David, Harris, Jonathan, and Le, Quynh‐Thu

Subjects
Clinical Research, Cancer, Prevention, Clinical Trials and Supportive Activities, Digestive Diseases, Good Health and Well Being, Adult, Aged, Carcinoma, Squamous Cell, Chemoradiotherapy, Clinical Trials as Topic, Female, Follow-Up Studies, Humans, Male, Middle Aged, Oropharyngeal Neoplasms, Papillomaviridae, Papillomavirus Infections, Patient Selection, Prognosis, Prospective Studies, Retrospective Studies, Risk Assessment, Survival Rate, head and neck cancer, human papillomavirus, oropharyngeal cancer, overall survival, progression-free survival, Radiation Therapy Oncology Group, therapeutic deintensification, therapeutic deescalation, risk stratification, recursive partititioning analysis, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundRadiation Therapy Oncology Group (RTOG)-0129 recursive partitioning analysis was the basis for risk-based therapeutic intensification trials for oropharyngeal cancer (OPC). To the authors' knowledge, the question of whether RTOG-0129 overall survival (OS) estimates for low-risk, intermediate-risk, and high-risk groups are similar in other data sets or applicable to progression-free survival (PFS) is unknown. Therefore, the authors evaluated whether survival differences between RTOG-0129 risk groups persist at 5 years, are reproducible in an independent clinical trial, and are applicable to PFS, and whether toxicities differ across risk groups.MethodsProspective randomized clinical trials were analyzed retrospectively. RTOG-0129 evaluated standard versus accelerated fractionation radiotherapy concurrent with cisplatin. RTOG-0522 compared the combination of cisplatin and accelerated fractionation with or without cetuximab. Patients with OPC with available p16 status and tobacco history were eligible.ResultsThere was a total of 260 patients and 287 patients, respectively, from RTOG-0129 and RTOG-0522, with median follow-ups for surviving patients of 7.9 years (range, 1.7-9.9 years) and 4.7 years (range, 0.1-7.0 years), respectively. Previous OS differences in RTOG-0129 persisted at 5 years. In RTOG-0522, the 5-year OS rates for the low-risk, intermediate-risk, and high-risk groups were 88.1%, 69.9%, and 45.1%, respectively (P for trend, 6 cm lymph nodes), the 5-year OS and PFS rates were 93.8% and 82.2%, respectively. Overall rates of acute and late toxicities were similar by risk group.ConclusionsRTOG-0129 risk groups persisted at 5 years and were reproducible in RTOG-0522. However, there was variability in the estimates. These data underscore the importance of long-term follow-up and appropriate patient selection in therapeutic deintensification trials.

Published
2019

19. Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy

Author

Taku, Nicolette, Chronowski, Gregory, Brandon Gunn, G., Morrison, William H., Gross, Neil D., Moreno, Amy C., Ferrarotto, Renata, Frank, Steven J., Fuller, C. David, Goepfert, Ryan P., Phan, Jack, Lai, Stephen Y., Reddy, Jay P., Rosenthal, David I., and Garden, Adam S.

Published
2022
Full Text
View/download PDF

21. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy

Author

van Dijk, Lisanne V., Frank, Steven J., Yuan, Ying, Gunn, Brandon, Moreno, Amy C., Mohamed, Abdallah S.R., Preston, Kathryn E., Qing, Yun, Spiotto, Michael T., Morrison, William H., Lee, Anna, Phan, Jack, Garden, Adam S., Rosenthal, David I., Langendijk, Johannes A., and Fuller, Clifton D.

Published
2022
Full Text
View/download PDF

23. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer

Author

Fakhry, Carole, Zhang, Qiang, Nguyen-Tân, Phuc Felix, Rosenthal, David I, Weber, Randal S, Lambert, Louise, Trotti, Andy M, Barrett, William L, Thorstad, Wade L, Jones, Christopher U, Yom, Sue S, Wong, Stuart J, Ridge, John A, Rao, Shyam SD, Bonner, James A, Vigneault, Eric, Raben, David, Kudrimoti, Mahesh R, Harris, Jonathan, Le, Quynh-Thu, and Gillison, Maura L

Subjects
Dental/Oral and Craniofacial Disease, Digestive Diseases, Cancer, Clinical Research, Prevention, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemoradiotherapy, Cohort Studies, Disease-Free Survival, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Nomograms, Organoplatinum Compounds, Oropharyngeal Neoplasms, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Squamous Cell Carcinoma of Head and Neck, Survival Rate, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Treatment of oropharyngeal squamous cell carcinoma (OPSCC) is evolving toward risk-based modification of therapeutic intensity, which requires patient-specific estimates of overall survival (OS) and progression-free survival (PFS). Methods To develop and validate nomograms for OS and PFS, we used a derivation cohort of 493 patients with OPSCC with known p16 tumor status (surrogate of human papillomavirus) and cigarette smoking history (pack-years) randomly assigned to clinical trials using platinum-based chemoradiotherapy (NRG Oncology Radiation Therapy Oncology Group [RTOG] 0129 and 0522). Nomograms were created from Cox models and internally validated by use of bootstrap and cross-validation. Model discrimination was measured by calibration plots and the concordance index. Nomograms were externally validated in a cohort of 153 patients with OPSCC randomly assigned to a third trial, NRG Oncology RTOG 9003. Results Both models included age, Zubrod performance status, pack-years, education, p16 status, and T and N stage; the OS model also included anemia and age × pack-years interaction; and the PFS model also included marital status, weight loss, and p16 × Zubrod interaction. Predictions correlated well with observed 2-year and 5-year outcomes. The uncorrected concordance index was 0.76 (95% CI, 0.72 to 0.80) for OS and 0.70 (95% CI, 0.66 to 0.74) for PFS, and bias-corrected indices were similar. In the validation set, OS and PFS models were well calibrated, and OS and PFS were significantly different across tertiles of nomogram scores (log-rank P = .003;< .001). Conclusion The validated nomograms provided useful prediction of OS and PFS for patients with OPSCC treated with primary radiation-based therapy.

Published
2017

24. Comparison of Machine Leaning Models for Prediction of Acute Pain Severity and On-Treatment Opioid Utilization in Oral Cavity and Oropharyngeal Cancer Patients Receiving Radiation Therapy: Exploratory Analysis from a Large-Scale Retrospective Cohort

Author

Salama, Vivian, primary, Humbert-Vidan, Laia, additional, Godinich, Brandon, additional, Wahid, Kareem A., additional, ElHabashy, Dina M., additional, Naser, Mohamed A., additional, He, Renjie, additional, Mohamed, Abdallah S.R., additional, Sahli, Ariana J., additional, Hutcheson, Katherine A., additional, Gunn, Gary Brandon, additional, Rosenthal, David I., additional, Fuller, Clifton D., additional, and Moreno, Amy C., additional

Published
2024
Full Text
View/download PDF

25. Detection of Alteration in Carotid Artery Volumetry Using Standard-of-care Computed Tomography Surveillance Scans Following Unilateral Radiation Therapy for Early-stage Tonsillar Squamous Cell Carcinoma Survivors: A Cross-Sectional Internally-Matched Carotid Isodose Analysis

Author

Koutroumpakis, Efstratios, primary, Naser, Mohamed A., additional, Mohamed, Abdallah Sherif Radwan, additional, Eraj, Salman A., additional, Jarre, Andrea, additional, Shiao, Jay C., additional, Jomaa, Mona K., additional, Perni, Subha, additional, Phan, Jack P., additional, Morrison, William H., additional, Frank, Steven J., additional, Gunn, G. Brandon, additional, Garden, Adam S., additional, Deswal, Anita, additional, Abe, Jun-ichi, additional, Rosenthal, David I., additional, Mouhayar, Elie, additional, and Fuller, Clifton D., additional

Published
2024
Full Text
View/download PDF

27. International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Author

Ng, Wai Tong, Soong, Yoke Lim, Ahn, Yong Chan, AlHussain, Hussain, Choi, Horace C.W., Corry, June, Grégoire, Vincent, Harrington, Kevin J., Hu, Chao Su, Jensen, Kenneth, Kwong, Dora L., Langendijk, Johannes A., Le, Quynh Thu, Lee, Nancy Y., Lin, Jin Ching, Lu, Tai Xiang, Mendenhall, William M., O’Sullivan, Brian, Ozyar, Enis, Pan, Jian Ji, Peters, Lester J., Poh, Sharon S., Rosenthal, David I., Sanguineti, Giuseppe, Tao, Yungan, Wee, Joseph T., Yom, Sue S., Chua, Melvin L.K., and Lee, Anne W.M.

Published
2021
Full Text
View/download PDF

28. 18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer

Author

Elhalawani, Hesham, Cardenas, Carlos E., Volpe, Stefania, Barua, Souptik, Stieb, Sonja, Rock, Calvin B., Lin, Timothy, Yang, Pei, Wu, Haijun, Zaveri, Jhankruti, Elgohari, Baher, Abdallah, Lamiaa E., Jethanandani, Amit, Mohamed, Abdallah S.R., Court, Laurence E., Hutcheson, Katherine A., Brandon Gunn, G., Rosenthal, David I., Frank, Steven J., Garden, Adam S., Rao, Arvind, and Fuller, Clifton D.

Published
2021
Full Text
View/download PDF

29. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores – A pooled analysis of RTOG 0129 and 0522

Author

Awan, Musaddiq J., Gittleman, Haley, Barnholtz-Sloan, Jill, Machtay, Mitchell, Nguyen-Tan, Phuc Felix, Rosenthal, David I., Schultz, Christopher, Huth, Bradley J., Thorstad, Wade L, Frank, Steven J., Kim, Harold, Foote, Robert L., Lango, Miriam N., Shenouda, George, Suntharalingam, Mohan, Harris, Jonathan, Zhang, Qiang, Le, Quynh-Thu, and Yao, Min

Published
2021
Full Text
View/download PDF

32. Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129

Author

Galloway, Thomas J, Zhang, Qiang, Nguyen-Tan, Phuc Felix, Rosenthal, David I, Soulieres, Denis, Fortin, André, Silverman, Craig L, Daly, Megan E, Ridge, John A, Hammond, J Alexander, and Le, Quynh-Thu

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Dental/Oral and Craniofacial Disease, Clinical Research, Rare Diseases, Antineoplastic Agents, Biomarkers, Tumor, Chemoradiotherapy, Cisplatin, Combined Modality Therapy, Cyclin-Dependent Kinase Inhibitor p16, Female, Humans, Internationality, Lymph Nodes, Male, Neck, Neck Dissection, Oropharyngeal Neoplasms, Prevalence, Prognosis, Reproducibility of Results, Sensitivity and Specificity, Survival Rate, Treatment Outcome, Other Physical Sciences, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeTo determine the relationship between p16 status and the regional response of patients with node-positive oropharynx cancer treated on NRG Oncology RTOG 0129.Methods and materialsPatients with N1-N3 oropharynx cancer and known p16 status who underwent treatment on RTOG 0129 were analyzed. Pathologic complete response (pCR) rates in patients treated with a postchemoradiation neck dissection (with p16-positive or p16-negative cancer) were compared by Fisher exact test. Patients managed expectantly were compared with those treated with a neck dissection.ResultsNinety-nine (34%) of 292 patients with node-positive oropharynx cancer and known p16 status underwent a posttreatment neck dissection (p16-positive: n=69; p16-negative: n=30). The remaining 193 patients with malignant lymphadenopathy at diagnosis were observed. Neck dissection was performed a median of 70 (range, 17-169) days after completion of chemoradiation. Neither the pretreatment nodal stage (P=.71) nor the postradiation, pre-neck dissection clinical/radiographic neck assessment (P=.42) differed by p16 status. A pCR was more common among p16-positive patients (78%) than p16-negative patients (53%, P=.02) and was associated with a reduced incidence of local-regional failure (hazard ratio 0.33, P=.003). On multivariate analysis of local-regional failure, a test for interaction between pCR and p16 status was not significant (P=.37). One-hundred ninety-three (66%) of 292 of initially node-positive patients were managed without a posttreatment neck dissection. Development of a clinical (cCR) was not significantly influenced by p16-status (P=.42). Observed patients with a clinical nodal CR had disease control outcomes similar to those in patients with a pCR neck dissection.ConclusionsPatients with p16-positive tumors had significantly higher pCR and locoregional control rates than those with p16-negative tumors.

Published
2016

34. The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors

Author

Stieb, Sonja, Perez-Martinez, Ismael, Mohamed, Abdallah S.R., Rock, Stockton, Bajaj, Nimit, Deshpande, Tanaya S., Zaid, Mohamed, Garden, Adam S., Goepfert, Ryan P., Cardoso, Richard, Ferrarotto, Renata, Reddy, Jay P., Phan, Jack, Morrison, William H., Rosenthal, David I., Koay, Eugene J., Frank, Steven J., Fuller, C. David, and Gunn, G. Brandon

Published
2020
Full Text
View/download PDF

36. A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods

Author

Zaid, Mohamed, Koay, Eugene J., Bajaj, Nimit, Mathew, Ryan, Xiao, Lianchun, Agrawal, Anshuman, Fernandes, Pearl, Burrows, Hannah, Roach, Millicent A., Wilke, Christopher T., Chung, Caroline, Fuller, Clifton D., Phan, Jack, Gunn, G. Brandon, Morrison, William H., Garden, Adam S., Frank, Steven J., Rosenthal, David I., Andersen, Michael, Otun, Adegbenga, and Chambers, Mark S.

Published
2020
Full Text
View/download PDF

37. Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?

Author

Stieb, Sonja, Mohamed, Abdallah S.R., Deshpande, Tanaya S., Harp, Jared, Greiner, Benjamin, Garden, Adam S., Goepfert, Ryan P., Cardoso, Richard, Ferrarotto, Renata, Phan, Jack, Reddy, Jay P., Morrison, William H., Rosenthal, David I., Frank, Steven J., Fuller, C. David, and Brandon Gunn, G.

Published
2020
Full Text
View/download PDF

38. Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases

Author

Ng, Sweet Ping, Cardenas, Carlos E, Elhalawani, Hesham, Pollard, Courtney, III, Elgohari, Baher, Fang, Penny, Meheissen, Mohamed, Guha-Thakurta, Nandita, Bahig, Houda, Johnson, Jason M., Kamal, Mona, Garden, Adam S, Reddy, Jay P., Su, Shirley Y., Ferrarotto, Renata, Frank, Steven J., Brandon Gunn, G., Moreno, Amy C., Rosenthal, David I., Fuller, Clifton D., and Phan, Jack

Published
2020
Full Text
View/download PDF

42. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma

Author

Lee, Anne W., Ng, Wai Tong, Pan, Jian Ji, Chiang, Chi-Leung, Poh, Sharon S., Choi, Horace C., Ahn, Yong Chan, AlHussain, Hussain, Corry, June, Grau, Cai, Grégoire, Vincent, Harrington, Kevin J., Hu, Chao Su, Kwong, Dora L., Langendijk, Johannes A., Le, Quynh Thu, Lee, Nancy Y., Lin, Jin Ching, Lu, Tai Xiang, Mendenhall, William M., O'Sullivan, Brian, Ozyar, Enis, Peters, Lester J., Rosenthal, David I., Sanguineti, Giuseppe, Soong, Yoke Lim, Tao, Yungan, Yom, Sue S., and Wee, Joseph T.

Published
2019
Full Text
View/download PDF

44. Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity

Author

Nguyen-Tan, Phuc Felix, Zhang, Qiang, Ang, K Kian, Weber, Randal S, Rosenthal, David I, Soulieres, Denis, Kim, Harold, Silverman, Craig, Raben, Adam, Galloway, Thomas J, Fortin, André, Gore, Elizabeth, Westra, William H, Chung, Christine H, Jordan, Richard C, Gillison, Maura L, List, Marcie, and Le, Quynh-Thu

Subjects
Clinical Trials and Supportive Activities, Dental/Oral and Craniofacial Disease, Prevention, Clinical Research, Rare Diseases, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Chemoradiotherapy, Cisplatin, Disease Progression, Disease-Free Survival, Dose Fractionation, Radiation, Female, Head and Neck Neoplasms, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Risk Factors, Time Factors, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC).Patients and methodsPatients had stage III to IV carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Radiation therapy schedules were 70 Gy in 35 fractions over 7 weeks (SFX) or 72 Gy in 42 fractions over 6 weeks (AFX-C). Cisplatin doses were 100 mg/m(2) once every 3 weeks for two (AFX-C) or three (SFX) cycles. Toxicities were scored by using National Cancer Institute Common Toxicity Criteria 2.0 and the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer criteria. Overall survival (OS) and progression-free survival (PFS) rates were estimated by using the Kaplan-Meier method and were compared by using the one-sided log-rank test. Locoregional failure (LRF) and distant metastasis (DM) rates were estimated by using the cumulative incidence method and Gray's test.ResultsIn all, 721 of 743 patients were analyzable (361, SFX; 360, AFX-C). At a median follow-up of 7.9 years (range, 0.3 to 10.1 years) for 355 surviving patients, no differences were observed in OS (hazard ratio [HR], 0.96; 95% CI, 0.79 to 1.18; P = .37; 8-year survival, 48% v 48%), PFS (HR, 1.02; 95% CI, 0.84 to 1.24; P = .52; 8-year estimate, 42% v 41%), LRF (HR, 1.08; 95% CI, 0.84 to 1.38; P = .78; 8-year estimate, 37% v 39%), or DM (HR, 0.83; 95% CI, 0.56 to 1.24; P = .16; 8-year estimate, 15% v 13%). For oropharyngeal cancer, p16-positive patients had better OS than p16-negative patients (HR, 0.30; 95% CI, 0.21 to 0.42; P < .001; 8-year survival, 70.9% v 30.2%). There were no statistically significant differences in the grade 3 to 5 acute or late toxicities between the two arms and p-16 status.ConclusionWhen combined with cisplatin, AFX-C neither improved outcome nor increased late toxicity in patients with LA-HNC. Long-term high survival rates in p16-positive patients with oropharyngeal cancer support the ongoing efforts to explore deintensification.

Published
2014

45. Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles

Author

Christopherson, Kaitlin M., Ghosh, Alokananda, Mohamed, Abdallah Sherif Radwan, Kamal, Mona, Gunn, G. Brandon, Dale, Timothy, Kalpathy-Cramer, Jayashree, Messer, Jay, Garden, Adam S., Elhalawani, Hesham, Frank, Steven J., Lewin, Jan, Morrison, William H., Phan, Jack, Gross, Neil, Ferrarotto, Renata, Weber, Randal S., Rosenthal, David I., Lai, Stephen Y., Hutcheson, Katherine, Fuller, Clifton David, Radwan Mohamed, Abdallah Sherif, Marai, G. Elisabeta (Liz), Canahuate, Guadalupe, Vock, David M., and Fuller, David

Published
2019
Full Text
View/download PDF

48. Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating

Author

Kamal, Mona, Rosenthal, David I., Batra, Aakash, Volpe, Stefania, Elgohari, Baher, Goepfert, Ryan P., Garden, Adam S., Phan, Jack, Eraj, Salman, Dursteler, Amy, Williams, Bowman, Smith, Joshua, Aymard, Jeremy, Berends, Joel, White, Aubrey, Jethanandani, Amit, Cardenas, Carlos E., Frank, Steven J., Morrison, William H., Sturgis, Erich M., Cleeland, Charles S., Mendoza, Tito R., Mohamed, Abdallah S.R., Fuller, Clifton D., and Gunn, G. Brandon

Published
2019
Full Text
View/download PDF

50. A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial

Author

Meheissen, Mohamed A.M., Mohamed, Abdallah S.R., Kamal, Mona, Hernandez, Mike, Volpe, Stefania, Elhalawani, Hesham, Barrow, Martha P., Ding, Yao, Wang, Jihong, Davuluri, Raj, Rostom, Yousri, Hegazy, Neamat, Gunn, G. Brandon, Lai, Stephen Y., Garden, Adam S., Lewin, Jan S., Rosenthal, David I., Frank, Steven J., Fuller, Clifton D., and Hutcheson, Katherine A.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results